With psychedelics and psychedelic-assisted psychotherapy showing promise as potential treatments for mental health conditions, skilled facilitators who can provide therapy for patients and in clinical trials...
Will Alberta’s new regulatory framework for the delivery of psychedelic therapies pave the way for their integration into the healthcare system, or will it create a...
Apex Labs has been granted approval by Health Canada for the first North American take-home multi-dose psilocybin clinical trial evaluating the safety and efficacy of APEX-52...
Biopharmaceutical company, Ceruvia Lifesciences, has announced the appointment of Stephen Hurst and David Steinberg to its Board of Directors, effective immediately.
Canadian biotechnology company, PharmAla Biotech, has submitted its pre-IND data meeting package to the US Food and Drug Administration (FDA) for its novel MDMA analogue.
New data has revealed that a single 25mg dose of COMPASS Pathways’ COMP360 psilocybin in combination with psychological support had a significant impact in reducing symptoms...
The Emerging Innovations in Psychedelic Healthcare conference, held by the team behind PSYCH Symposium, is bringing together a wealth of experts to evaluate and accelerate the...
On November 8, 2022, Colorado citizens will be casting their vote on the Natural Medicine Health Act 2022 which proposes to decriminalise and regulate the use...
Small Pharma has received approval to carry out a first-in-human Phase 1 trial with its injectable deuterated DMT candidate – SPL028 – from the UK Medicines...
Enosis, OVID and the MIND Foundation are launching an in-clinic pilot offering of psychedelic-augmented psychotherapy that will leverage Virtual Reality (VR) technology.
